does medicaid cover glp-1 Navigating Changes to Medication Coverage California Medi-Cal halts GLP-1 obesity

Description

Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication

Diabetes Obes Metab 24(8):15531564 Wharton S et al (2021) Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

Weight loss Available in NZ = Liraglutide high dose (Saxenda, daily injection) Self-funding needed ($500-600/month) Not available in NZ = Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro), as of May 2023 Side effects, particularly upper gastrointestinal, are common with GLP-1 agonist initiation

Food and Drug Administration (FDA) as an adjunct to lifestyle changes for weight management in people with obesity or overweight with a related medical complication such as high blood pressure